# T-Knife

Source: https://onco.cc/companies/t-knife/  
OnCo record `t-knife` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A Berlin company that engineers patients' T cells with receptors that recognise cancer, aiming at solid tumours. Its lead therapy targets PRAME, a marker found in many cancers, and its first trial is planned for 2026.

## Summary

T-Knife develops engineered T-cell therapies for solid tumours. Its lead candidate is a TCR-T therapy targeting PRAME, which the company says is found in cancers of the skin, uterus, ovaries, lungs, breasts, oesophagus, kidneys, cervix and head and neck; the T cells carry the company's added enhancements meant to improve fitness and persistence in the tumour. The company says a Phase 1 trial is planned to begin in 2026 after CTA approval, and it lists in vivo programmes as well. T-Knife was founded on technology from the Max Delbruck Center for Molecular Medicine and Charite, with co-founders Thomas Blankenstein and Elisa Kieback. An earlier Phase 1/2 trial of MAGE-A1-directed TCR-T cells in advanced solid tumours (NCT05430555, sponsor T-knife GmbH) is registered as terminated.

## Fields

- Kind: Company
- Last checked: 2026-11-04
- Also known as: T-knife; T-knife Therapeutics; T-knife GmbH; T-knife Therapeutics, Inc.
- HQ: Berlin
- Type: cell-therapy
- Website: https://www.t-knife.com/

## Notes

- Founding year not stated on the pages read.
- Andera Partners is added because its life sciences page carries a T-Knife testimonial among its portfolio companies; check whether that is enough.
- No product record: the PRAME TCR-T candidate is preclinical and NCT05430555 does not name a product code.
- Cancer ids left empty because no trial of the PRAME TCR-T candidate is registered.

## Sources

- Official website: https://www.t-knife.com/
- Pipeline page: https://www.t-knife.com/pipeline/
- About page: https://www.t-knife.com/about/
- Imprint (T-knife GmbH, Berlin): https://www.t-knife.com/imprint/
- ClinicalTrials.gov NCT05430555: https://clinicaltrials.gov/study/NCT05430555
- Andera Partners life sciences page: https://www.anderapartners.com/en/expertise/life-sciences-biotechnologies/
- RA Capital portfolio entry: https://www.racap.com/portfolio/t-knife

## Connected records

- fronts: [Cell Therapy](https://onco.cc/fronts/cell-therapy/), [Immunotherapy](https://onco.cc/fronts/immunotherapy/)
- technologies: [TCR-T cell therapy](https://onco.cc/technologies/tcr-t/)
- targets: [PRAME](https://onco.cc/targets/prame/)
- companies: [Andera Partners](https://onco.cc/companies/andera-partners/), [RA Capital Management](https://onco.cc/companies/ra-capital/)

---
JSON: https://onco.cc/api/v1/entities/t-knife.json